Document:

License Agreement - Board of Trustees of the Leland Stanford Junior University

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 EXHIBIT 10.5.1 
 [*] 
 The offer contained herein is valid for a license that is fully executed by February 28,
2002, and is subject to change without notice thereafter. 
 AGREEMENT 
 Effective as of February 1, 2002 (“Effective Date”), THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, a body having
corporate powers under the laws of the State of California (“STANFORD”), and SUNVAX, INC. a Delaware corporation having a principal place of business at 400 Hamilton Avenue, Palo Alto, CA 94305 (“LICENSEE”), agree as
follows: 
  

	1.	BACKGROUND 

  

	 	1.1	STANFORD has an assignment of certain patent applications and disclosures included within Licensed Patent(s), as hereinafter defined, relating to the treatment of certain diseases
by administration of a polynucleotide encoding an autoantigen [*] discovered in the laboratory of Dr. Lawrence Steinman (“Invention[s]”), 

  

	 	1.2	STANFORD has certain technical data, materials and information (“Technology”), as hereinafter defined, pertaining to Invention(s). 

  

	 	1.3	STANFORD desires to have the Technology and Invention(s) perfected and marketed at the earliest possible time in order that products resulting therefrom may be available for public
use and benefit. 

  

	 	1.4	LICENSEE desires a license under said Technology, Invention(s), and Licensed Patent(s) to develop, manufacture, use, and sell Licensed Product(s) in the Licensed Field of Use (as
defined herein) of therapeutics for treatment, including but not limited to prophylaxis, of certain diseases by administration of a polynucleotide encoding an autoantigen [*] and diagnostics for the diseases treated by such polynucleotide
administration. 

  

	 	1.5	The Technology and Invention(s) were made in the course of research supported by the National Institutes of Health. 

  

	2.	DEFINITIONS 

  

	 	2.1	“Exclusive” means that, subject to Article 4, STANFORD shall not grant further licenses in the Licensed Territory in the Licensed Field of Use. 

 

	 	2.2	 “Licensed Field of Use” means therapeutics for treatment, including but not limited to prophylaxis, of human or animal diseases by the administration of a

  

 1 

 [*] 
  

	 	 
polynucleotide encoding an autoantigen [*] and diagnostics for the diseases treated by such polynucleotide administration. 

  

	 	2.3	“Licensed Patent(s)” means all patent applications and patents now or hereafter, owned or controlled by STANFORD for the Invention(s) in the Licensed Field of Use, listed
in Appendix B, which may be updated from time to time. Licensed Patent(s) include any patent or patent application of any kind anywhere in the world and includes any corresponding foreign applications, divisions, continuations, Continuations-in-Part
(as further described herein), patents of addition, patents, substitutions, registrations, reexaminations, extensions or reissues. “Continuation-in-Part” shall mean a patent application that discloses subject matter disclosed in the
applications and/or disclosures existing at the Effective Date and shall be included in Licensed Patents in accordance with the procedure for future Invention(s) set forth in Appendix C. Future Invention(s) in the Licensed Field of Use shall be
included in Licensed Patent(s) in accordance with the procedure in Appendix C. The current STANFORD patent applications, disclosures and patents included within Licensed Patents are listed in attached Appendix B to this Agreement.

  

	 	2.4	“Licensed Product(s)” means any product or part thereof in the Licensed Field of Use, the manufacture, use, or sale of which: 

  

	 	(a)	Is covered by a valid claim of an issued, unexpired Licensed Patent(s) directed to the Invention(s). A claim of an issued, unexpired Licensed Patent(s) shall be presumed to be valid
unless and until it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken; 

  

	 	(b)	Is covered by a claim filed in good faith and being prosecuted in a pending application directed to the Invention(s); provided that if a claim of a pending application has not
issued as a claim of an issued patent within the Licensed Patent(s) within [*] after the filing date from which such claim takes priority, such pending claim shall no longer be a valid claim for purposes of this Agreement; or

  

	 	(c)	Incorporates any of the Technology. 

  

	 	2.5	“Licensed Territory” means worldwide. 

  

	 	2.6	 “Net Sales” means the gross revenue received by LICENSEE and/or sublicensee(s) from sale of Licensed Product(s), whether or not assembled (and without
excluding therefrom any components or subassemblies thereof, whatever their origin and whether or not patent impacted), less the following items but only insofar as they actually pertain to the disposition of such Licensed Product(s) by 

  

 2 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	 	 
LICENSEE or sublicensee(s), are included in such gross revenue, and are separately billed: 

  

	 	(a)	Import, export, excise and sales taxes, and custom duties; 

  

	 	(b)	Costs of insurance, packing, and transportation from the place of manufacture to the customer’s premises or point of installation; 

  

	 	(c)	Costs of installation at the place of use; 

  

	 	(d)	Credit for returns, allowances, or trades; and 

  

	 	(e)	bad debts. 

  

	 	2.7	“Sub-Field” means either a diagnostic or a therapeutic use of a Licensed Product. 

  

	 	2.8	“Technology” means existing technical data, know-how, material(s), processes, procedure(s), composition(s), device, method(s), formula, protocol(s), technique(s),
software, design, drawing or information, all as they relate or pertain to the Invention(s), including, but not limited to, the information contained in the Licensed Patent(s) and provided to the LICENSEE whether or not it is of a confidential
nature. 

  

	3.	GRANT 

  

	 	3.1	STANFORD hereby grants and LICENSEE hereby accepts a license under the Licensed Patent(s) and Technology in the Licensed Field of Use to make, have made, use, import, offer to sell
and sell Licensed Product(s) in the Licensed Territory. 

  

	 	3.2	Said license under the Licensed Patents is Exclusive, including the right to sublicense pursuant to Article 13, in the Licensed Field of Use for a term commencing as of the
Effective Date and ending upon expiration of the last to expire of Licensed Patent(s). Stanford agrees that it will not grant further licenses under or to the Technology. 

  

	 	3.3	STANFORD shall have the right to practice the Invention(s) and use the Technology for its own bona fide research, teaching and other educationally-related purposes, including
sponsored research and collaborations. STANFORD shall have the right to publish the scientific findings from research included in Technology and Licensed Patent(s). 

  

	4.	GOVERNMENT RIGHTS 

 This Agreement is subject
to all of the terms and conditions of Title 35 United States Code Sections 200 through 204, including an obligation that Licensed Product(s) sold or 

  

 3 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

 
produced in the United States be “manufactured substantially in the United States,” and LICENSEE agrees to take all reasonable action necessary on
its part as licensee to enable STANFORD to satisfy its obligation thereunder, relating to Invention(s). 
  

	5.	DILIGENCE 

  

	 	

					
	5.1	  	(a)	 	 As an inducement to STANFORD to enter into this Agreement, LICENSEE agrees to use its commercially reasonable efforts and diligence to proceed with the
development, manufacture, and sale or lease of Licensed Product(s) and to diligently develop markets for the Licensed Product(s). For purposes of clarification, the efforts and diligence of a sublicensee shall fulfill LICENSEE’S obligations
hereunder. LICENSEE shall use its commercially reasonable efforts to (directly or indirectly) (i) commence Phase I Clinical Trials of a therapeutic using the technology licensed hereunder within [*] of the Effective Date; and (ii) offer
(directly or indirectly) one therapeutic Licensed Product for commercial sale prior to [*]. In addition, LICENSEE shall use its commercially reasonable efforts to offer (directly or indirectly) one diagnostic Licensed Product for commercial sale
prior to [*]. STANFORD may terminate this Agreement if LICENSEE or a sublicensee(s) has not sold Licensed Product(s) for a period of [*] after first commercial sale of Licensed Product from a particular Sub-field.

  

	 	(b)	LICENSEE agrees that in the event that LICENSEE or its sublicensee is not able to meet the foregoing milestones, then STANFORD may convene a discussion with LICENSEE to review and
approve changes to time schedules for diligence milestones based on factors raised through the progress report process and taking into account that LICENSEE has an ongoing and active research, development, manufacturing, marketing or sublicensing
program (as appropriate), directed toward the research, development, production and/or sale of a Licensed Product. 

  

	 	(c)	If LICENSEE fails to materially meet the diligence obligations of Section 5.1 subparagraph (a), subject to the provisions of Section 5.1 subparagraph (b), and
LICENSEE is unable or unwilling to serve a Sub-Field where there is a willing sublicensee for such Sub-Field, which sublicensee is identified in writing by STANFORD, then LICENSEE agrees to negotiate a sublicense with such party on mutually
acceptable terms and conditions to LICENSEE. 

  

	 	5.2	 Progress Report - On or before February 15 of each year until first commercial sale of a Licensed Product by LICENSEE or a sublicensee, LICENSEE shall
make a written annual report to STANFORD covering the preceding calendar year, regarding the progress of LICENSEE or sublicensee toward commercial sale of Licensed Product(s). Such report shall include, as a minimum, information sufficient to enable
STANFORD to satisfy reporting requirements of the U.S. Government under CFR Title 37, Section 401 and for STANFORD to ascertain progress by LICENSEE toward meeting the diligence requirements of this Article 

  

 4 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	 	 
5. STANFORD agrees that LICENSEE’s business plan and any reports provided to STANFORD are LICENSEE’s confidential and proprietary documents and
STANFORD will hold in confidence and not make use of such confidential information for any purpose other than those permitted by this Agreement. 

  

	 	5.3	STANFORD’s Diligent Efforts. STANFORD shall be responsible for and shall control, [*], except as provided in Section 6.9 below, the preparation, filing, prosecution and
maintenance of the Licensed Patent(s). STANFORD shall diligently and promptly apply for, seek prompt issuance of, and maintain (including payment of annuities to keep foreign applications in force) during the term of this Agreement, the Licensed
Patents. LICENSEE desires that foreign filings be made on the Inventions and STANFORD shall work closely with LICENSEE to ensure that such filings are made timely and in the order of priority reasonably requested by LICENSEE. STANFORD shall or shall
cause its patent counsel to give LICENSEE an opportunity to review and comment on the text of each patent application within the Licensed Patents before filing, and shall or shall cause its patent counsel to provide LICENSEE with a copy of such
patent application as filed, together with notice of its filing date and serial number. LICENSEE shall cooperate with STANFORD, execute all lawful papers and instruments and make all rightful oaths and declarations as may be necessary in the
preparation, prosecution and maintenance of the Licensed Patents. In the event that STANFORD desires to abandon any patent or patent application within the Licensed Patents, or take any action that would substantially effect the scope or validity of
the rights under such patent or patent application, STANFORD shall provide notice to LICENSEE a reasonable time before such abandonment or other action and review it with LICENSEE as reasonably requested, and incorporate reasonable comments by
LICENSEE thereon. A patent or patent application within the Licensed Patents may only be abandoned upon the mutual written agreement of the parties, provided, however, no such mutual written agreement is required when a patent application is
abandoned for the purpose of filing a continuing application. 

  

	6.	ROYALTIES 

  

	 	6.1	LICENSEE agrees to pay to STANFORD a noncreditable, nonrefundable license issue royalty of [*] Dollars ($[*]) within [*] of the closing of LICENSEE’s first round of financing
provided such first round of financing is for at least [*] dollars. LICENSEE anticipates that the closing of LICENSEE’S first round of financing will occur within [*] of the Effective Date. If such license issue royalty is not paid by [*],
Stanford may terminate this Agreement. In addition, LICENSEE agrees to pay to STANFORD a noncreditable, nonrefundable license royalty of [*] Dollars ($[*]) within [*] of the closing of LICENSEE’s second round of financing.

  

 5 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	 	6.2	LICENSEE will issue and convey to STANFORD, as consideration for the granting of the license from STANFORD to LICENSEE, fifty thousand (50,000) shares of Common Stock of
LICENSEE, which shares constitute [*] percent ([*] %) of the currently outstanding number of shares of capital stock of the LICENSEE within thirty (30) days after the date of this Agreement. A portion of the shares will be directly issued
to the inventors of the Inventions. STANFORD will provide the share distribution amount shortly after signing this Agreement. During the term of this Agreement, the LICENSEE will grant to STANFORD the same right to participate in future financing,
the same registration rights and the same information rights that the Company grants to an investor in a future round of financing. 

  

	 	6.3	LICENSEE shall pay to STANFORD the following amounts as annual royalty advances, each November 15 of the years set forth below: 

  

					
	 Year
	  	Amount of Annual
Royalty	 
	 [*]
	  	$	[	*]
	 [*]
	  	$	[	*]
	 [*] - each year thereafter during the term of this Agreement
	  	$	[	*]

 Each of the annual royalty advance payments set forth in this Section 6.3 are nonrefundable,
but they are fully creditable against earned royalties to the extent provided in Paragraph 6.7. 
  

	 	6.4	In addition, LICENSEE shall pay STANFORD earned royalties on Net Sales as follows: 

  

	 	(a)	[*] % of Net Sales of therapeutics; and 

  

	 	(b)	[*] % of Net Sales of diagnostics. 

  

	 	6.5	Licensee shall also pay creditable milestone payments as follows: 

  

	 	(a)	for therapeutics: 

  

	 	1.	$[*] upon the first to issue of Licensed Patent(s); and, 

  

	 	2.	$[*] upon FDA Approval of a Licensed Product. 

  

	 	(b)	for a diagnostic Licensed Product, $[*] upon first commercial sale. 

 LICENSEE shall be required to pay any milestone payment to STANFORD only once with respect to the first therapeutic or diagnostic Licensed Product. 
  

 6 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	 	6.6	No more than one earned royalty payment pursuant to Paragraph 6.4 shall be due with respect to a sale of a particular Licensed Product. No multiple royalties shall be payable
because any Licensed Product, or its manufacture, sale or use is covered by more than one valid claim. 

  

	 	6.7	Creditable payments pursuant to paragraph 6.5 and 6.3 under this Agreement shall be an offset to royalties otherwise owed by LICENSEE and will be applied by STANFORD against up to
[*] percent ([*]%) of each earned royalty payment which LICENSEE would be required to pay pursuant to Paragraph 6.4 until the entire credit is exhausted. Patent expenses that are not reimbursed are creditable against royalties due under paragraph
6.4. 

  

	 	6.8	The royalty on sales in currencies other than U.S. Dollars shall be calculated using the appropriate foreign exchange rate for such currency quoted by the Bank of America (San
Francisco) foreign exchange desk, on the close of business on the last banking day of each calendar quarter. Royalty payments to STANFORD shall be in U.S. Dollars. All non-U.S. taxes related to royalty payments shall be paid by LICENSEE and are not
deductible from the payments due STANFORD. 

  

	 	6.9	Within thirty (30) days after receipt of a statement from STANFORD, LICENSEE shall reimburse STANFORD for all reasonable costs incurred and paid by Stanford after
August 1, 2001 in connection with the preparation, filing and prosecution of all patent applications and maintenance of patents within Licensed Patent(s) covering the Invention(s). 

  

	 	6.10	Earned Royalties on Net Sales due pursuant to Paragraph 6.4 shall be payable on a country-by-country and Licensed Product-by-Licensed Product basis until the expiration of the
last-to-expire Valid Claim covering such Licensed Product in such country. In the event that a Licensed Product is made in a country where a Licensed Patent exists and is sold in a country where a Licensed Patent does not exist, such Licensed
Product will be a royalty-bearing product under this Agreement. 

  

	 	6.11	Before the anticipated issuance of Licensed Patent(s) related to the Licensed Product(s), the “license fees” and “royalties” discussed hereunder are understood
by the parties to be fees paid for the reservation of the licenses granted hereunder, licenses for which the need only actually arises when and if Licensed Patents related to the Licensed Products issue in specified jurisdictions in the Territory.
If and when such Licensed Patents issue, the “licensee fees” and “royalties” discussed hereunder shall then be understood by the parties to be true “licensee fees” and “royalties” related to the licenses
granted hereunder, licenses for which the need shall then actually arise, in order to avoid infringement in the applicable jurisdiction. 

  

	7.	ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING 

  

 7 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	 	7.1	Quarterly Earned Royalty Payment and Report - Beginning with the first sale of a Licensed Product(s), LICENSEE shall make written reports (even if there are no sales) and
earned royalty payments to STANFORD within [*] after the end of each calendar quarter. This report shall be in the form of the report of Appendix A and shall state the number, description, and aggregate Net Sales of Licensed Product(s) during such
completed calendar quarter, and resulting calculation pursuant to Paragraph 6.4 of earned royalty payment due STANFORD for such completed calendar quarter. Concurrent with the making of each such report, LICENSEE shall include payment due STANFORD
of royalties for the calendar quarter covered by such report. 

  

	 	7.2	LICENSEE also agrees to make a written report to STANFORD within [*] after the expiration of the license pursuant to Section 3.2. LICENSEE shall continue to make reports
pursuant to the provisions of this Section 7.2 concerning royalties payable in accordance with Article 6 in connection with the sale of Licensed Product(s) after expiration of the license, until such time as all such Licensed Product(s)
produced under the license have been sold or destroyed. Concurrent with the submittal of each post-termination report, LICENSEE shall pay STANFORD all applicable royalties. 

  

	 	7.3	Accounting - LICENSEE agrees to keep and maintain records for a period of three (3) years showing the manufacture, sale, use, and other disposition of products sold or
otherwise disposed of under the license herein granted. Such records will include general ledger records showing cash receipts and expenses, and records which include production records, customers, serial numbers, and related information in
sufficient detail to enable the royalties payable hereunder by LICENSEE to be determined. LICENSEE further agrees to permit its books and records to be examined by STANFORD from time to time to the extent necessary to verify reports provided for in
Paragraph 7.1 and 7.2. Such examination is to be made by STANFORD or its designee, at the expense of STANFORD, except in the event that the results of the audit reveal an underreporting of royalties due STANFORD of five percent (5%) or more,
then the audit costs shall be paid by LICENSEE. 

  

	 	7.4	LICENSEE agrees to conduct an independent audit of sales and royalties at least every [*] if annual sales of the Licensed Product(s) are over [*] dollars. The audit shall address,
at a minimum, the amount of gross sales by or on behalf of LICENSEE during the audit period, the amount of funds owed to STANFORD under this Agreement, and whether the amount owed has been paid to STANFORD and is reflected in the records of the
LICENSEE. A report by the auditor shall be submitted promptly to STANFORD on completion. LICENSEE shall pay for the entire cost of the audit. 

  

	8.	NEGATION OF WARRANTIES 

  

 8 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	 	8.1	Nothing in this Agreement is or shall be construed as: 

  

	 	(a)	A warranty or representation by STANFORD as to the validity or scope of any Licensed Patent(s); 

  

	 	(b)	A warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents,
copyrights, and other rights of third parties; 

  

	 	(c)	An obligation to bring or prosecute actions or suits against third parties for infringement, except to the extent and in the circumstances described in Article 12;

  

	 	(d)	Granting by implication, estoppel, or otherwise any licenses or rights under patents or other rights of STANFORD or other persons other than Licensed Patent(s), regardless of
whether such patents or other rights are dominant or subordinate to any Licensed Patent(s); or 

  

	 	(e)	An obligation to furnish any technology or technological information other than the Technology. 

  

	 	8.2	Except for the rights, if any, of the Government of the United States of America, as set forth in Section 4, STANFORD represents and warrants that, to the best of its
knowledge: (a) STANFORD is the owner of the entire right, title, and interest in and to Licensed Subject Matter; (b) STANFORD has the sole right and authority to enter into this License Agreement and grant the rights and licenses
hereunder; (c) STANFORD has not previously granted and will not grant any rights in the Licensed Subject Matter or Licensed Products that are inconsistent with the rights and licenses granted to LICENSEE herein; and, (d) Schedule B
includes all patents and patent applications within Licensed Patents existing as of the Effective Date and STANFORD owns no rights in any other patent or patent application, that claim any invention relating to the administration of a polynucleotide
encoding an autoantigen [*] recognizing STANFORD has no practical means to check whether such patent or patent application exist. 

  

	 	8.3	Except as expressly set forth in this Agreement, STANFORD MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE LICENSED PRODUCT(S) WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES. 

 

 9 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	 	8.4	LICENSEE agrees that nothing in this Agreement grants LICENSEE any express or implied license or right under or to U.S. Patent [*] or any patent application corresponding thereto.

  

	9.	INDEMNITY 

  

	 	9.1	LICENSEE agrees to indemnify, hold harmless, and defend STANFORD, STANFORD Hospitals and Clinics and Stanford Health Services and their respective trustees, officers, employees,
students, and agents against any and all claims for death, illness, personal injury, property damage, and improper business practices arising out of the manufacture, use, sale, or other disposition of Invention(s), Licensed Patent(s), Licensed
Product(s), or Technology by LICENSEE or sublicensee(s), or their customers. 

  

	 	9.2	EXCEPT FOR ANY BREACH OF THE LICENSE TERMS BY LICENSEE AND FOR ANY CLAIM FOR WHICH LICENSEE HAS AGREED TO INDEMNIFY STANFORD, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY
INDIRECT, SPECIAL, CONSEQUENTIAL OR OTHER DAMAGES WHATSOEVER, WHETHER GROUNDED IN TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, CONTRACT OR OTHERWISE ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR LICENSEES USE OF THE LICENSED PATENTS,
TECHNOLOGY, OR LICENSED PRODUCTS UNDER ANY THEORY OF LIABILITY. STANFORD SHALL NOT HAVE ANY RESPONSIBILITIES OR LIABILITIES WHATSOEVER WITH RESPECT TO THE RESEARCH, DEVELOPMENT, MANUFACTURE, USE, OR SALE OF LICENSED PRODUCT(S) HEREUNDER.

  

	 	9.3	LICENSEE shall at all times comply, through insurance or self-insurance, with all statutory workers’ compensation and employers’ liability requirements covering any and
all employees with respect to activities performed under this Agreement. 

  

	 	9.4	 In addition to the foregoing, LICENSEE shall maintain, during the term of this Agreement, Comprehensive General Liability Insurance, including Products Liability
Insurance, with reputable and financially secure insurance carrier(s) to cover the activities of LICENSEE and its sublicensee(s). Such insurance shall provide minimum limits of liability of $[*] and shall include STANFORD, Stanford Hospitals and
Clinics, Stanford Health Services, their trustees, directors, officers, employees, students, and agents as additional insureds. Such insurance shall be written to cover claims incurred, discovered, manifested, or made during or after the expiration
of this Agreement and should be placed with carriers with ratings of at least A- as rated by A.M. Best. Within 15 days of the Effective Date of this Agreement, LICENSEE shall furnish a Certificate of Insurance evidencing primary coverage and
additional insured requirements and requiring thirty (30) days prior written notice of cancellation or material change to STANFORD. 

  

 10 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	 	 
LICENSEE shall advise STANFORD, in writing, that it maintains excess liability coverage (following form) over primary insurance for at least the minimum
limits set forth above. All such insurance of LICENSEE shall be primary coverage; insurance of STANFORD, Stanford Hospitals and Clinics, and Stanford Health Services shall be excess and noncontributory. 

  

	10.	MARKING 

 Prior to the issuance of patents on
the Invention(s), LICENSEE agrees to mark Licensed Products (or their containers or labels) made, sold, or otherwise disposed of by it under the license granted in this Agreement with the words “Patent Pending,” and following the issuance
of one or more patents, with the numbers of the Licensed Patent(s). 
  

	11.	STANFORD NAMES AND MARKS 

 LICENSEE agrees
not to identify STANFORD in any promotional advertising or other promotional materials to be disseminated to the public or any portion thereof or to use the name of any STANFORD faculty member, employee, or student or any trademark, service mark,
trade name, or symbol of STANFORD, Stanford Health Services or UCSF-Stanford Health Care, or that is associated with any of them, without STANFORD’s prior written consent. Any use of STANFORD’s name shall be limited to statements of fact
and shall not imply endorsement of LICENSEE’s products or services. 
  

	12.	INFRINGEMENT BY OTHERS: PROTECTION OF PATENTS 

  

	 	12.1	LICENSEE shall promptly inform STANFORD of any suspected infringement of any Licensed Patent(s) by a third party. During the Exclusive period of this Agreement, STANFORD and
LICENSEE each shall have the right to institute an action for infringement of the Licensed Patent(s) against such third party in accordance with the following: 

  

	 	(a)	If STANFORD and LICENSEE agree to institute suit jointly, the suit shall be brought in both their names, the out-of-pocket costs thereof shall be borne [*], and any recovery or
settlement shall be shared [*]. LICENSEE and STANFORD shall agree to the manner in which they shall exercise control over such action. STANFORD may, if it so desires, also be represented by separate counsel of its own selection, the fees for which
counsel shall be paid by STANFORD; 

  

	 	(b)	 In the absence of agreement to institute a suit jointly, STANFORD may institute suit, and, at its option, join LICENSEE as a plaintiff. If STANFORD decides to
institute suit, then it shall notify LICENSEE in writing. LICENSEE’s failure to notify STANFORD in writing, within fifteen (15) days after the date of the notice, that it will join in enforcing the patent pursuant to the provisions hereof,
shall be and be deemed 

  

 11 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	 	 
conclusively to be LICENSEE’s assignment to STANFORD of all rights, causes of action, and damages resulting from any such alleged infringement. [*]
shall bear [*] cost of such litigation and shall be entitled to retain [*] amount of any recovery or settlement; and 

  

	 	(c)	In the absence of agreement to institute a suit jointly and if STANFORD notifies LICENSEE that it has decided not to join in or institute a suit, as provided in (a) or
(b) above, LICENSEE may institute suit. [*] shall bear [*] cost of such litigation, [*] incurred by [*]. Any recovery in excess of litigation costs will be shared with STANFORD as follows: 

  

	 	1.	Any payment for past sales will be [*] to be [*] and LICENSEE will pay STANFORD [*] thereon at the [*] specified in Paragraph [*]; and, 

  

	 	2.	any payment which covers future sales will be deemed a [*] will be shared as specified in [*]. 

 LICENSEE and STANFORD agree to negotiate in good faith an appropriate compensation to STANFORD for any non-cash settlement or non-cash cross-license.
STANFORD will not share in the portion of the recovery, if any, that is payment for “willful infringement.” 
  

	 	12.2	Should either STANFORD or LICENSEE commence a suit under the provisions of Paragraph 12.1 and thereafter elect to abandon the same, it shall give timely notice to the other party
who may, if it so desires, continue prosecution of such suit, provided, however, that the sharing of expenses and any recovery in such suit shall be as agreed upon between STANFORD and LICENSEE. 

  

	13.	SUBLICENSE(S) 

  

	 	13.1	LICENSEE may grant sublicense(s) under the license grant hereunder. 

  

	 	13.2	Any sublicense(s) granted by LICENSEE under this Agreement shall be subject to terms and conditions of this Agreement, except: 

  

	 	(a)	Sublicense terms and conditions shall reflect that any sublicensee(s) shall not further sublicense; 

  

	 	(b)	The earned royalty rate specified in the sublicense(s) may be at higher rates than the rates in this Agreement; and, 

  

	 	(c)	Any such sublicense(s) also shall expressly include provisions for indemnification and limited warranties as mutually agreed in writing by STANFORD and LICENSEE.

  

 12 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

 Any such sublicense(s) also shall expressly include the provisions of Articles 8 and 9 for the
benefit of STANFORD and provide for the transfer of all obligations, including the payment of royalties specified in such sublicense(s), to STANFORD or its designee, in the event that this Agreement is terminated. 
  

	 	13.3	LICENSEE agrees to provide STANFORD for informational purposes only and subject to the execution of a confidentiality agreement protecting such disclosure, the form of sublicense
granted pursuant to this Article 13. 

  

	 	13.4	If this Agreement is terminated for any reason, all outstanding Sublicenses (but only to the extent of the rights sublicensed hereunder) will remain in full force and effect with
STANFORD as the licensor or sublicensor instead of LICENSEE. 

  

	 	13.5	LICENSEE may grant [*] Sublicenses or cross-licenses provided LICENSEE pays all royalties due STANFORD from sublicensee’s Net Sales. 

  

	14.	TERMINATION 

  

	 	14.1	LICENSEE may terminate this Agreement by giving STANFORD notice in writing at least thirty (30) days in advance of the effective date of termination selected by LICENSEE.

  

	 	14.2	Either party may terminate this Agreement in the event the other party has materially breached or defaulted in the performance of any of its obligations hereunder, and such default
has continued for ninety (90) days after written notice thereof was provided to the breaching party by the nonbreaching party. Any termination shall become effective at the end of such ninety (90) day period unless the breaching party has
cured any such breach or default prior to the expiration of such period. 

  

	 	14.3	Surviving any termination or expiration are: 

  

	 	(a)	LICENSEE’s obligation to pay royalties accrued or accruable; 

  

	 	(b)	Any cause of action or claim of LICENSEE or STANFORD, accrued or to accrue, because of any breach or default by the other party; 

  

	 	(c)	The provisions of paragraph 14.4, Articles 7, 8, and 9 and any other provisions that by their nature are intended to survive; and 

  

	 	(d)	All Sublicensees granted pursuant to the license granted hereunder. 

  

	 	14.4	Upon the expiration or earlier termination of this Agreement, LICENSEE will have the right to continue selling any Licensed Products in stock on the effective date of such
expiration or termination and shall pay royalties based on Net Sales of such Licensed Products in accordance with the provisions of Section 6.4. 

  

 13 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	15.	ASSIGNMENT 

 Except as otherwise expressly
provided under this Agreement, neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred (whether voluntarily, by operation of law or otherwise), without the prior express written consent of the other
party; provided, however, that either party may, without such consent, assign this Agreement and its rights and obligations hereunder in connection with the transfer or sale of all or substantially all of its business, or in the event of its merger,
consolidation, change in control or similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment or transfer in violation of this Article 15 shall be void. 
  

	16.	ARBITRATION 

  

	 	16.1	Any controversy arising under or related to this Agreement, and any disputed claim by either party against the other under this Agreement excluding any dispute relating to patent
validity or infringement arising under this Agreement, shall be settled by arbitration in accordance with the Licensing Agreement Arbitration Rules of the American Arbitration Association. 

  

	 	16.2	Upon request by either party, arbitration will be by a third party arbitrator mutually agreed upon in writing by LICENSEE and STANFORD within thirty (30) days of such
arbitration request. Judgement upon the award rendered by the arbitrator shall be final and nonappealable and may be entered in any court having jurisdiction thereof. 

  

	 	16.3	The parties shall be entitled to discovery in like manner as if the arbitration were a civil suit in the California Superior Court. The Arbitrator may limit the scope, time and/or
issues involved in discovery. 

  

	 	16.4	Any arbitration shall be held at Stanford, California, unless the parties hereto mutually agree in writing to another place. 

  

	17.	NOTICES 

 All notices under this Agreement
shall be deemed to have been fully given when done in writing and deposited in the United States mail, registered or certified, and addressed as follows: 
  

							
		 	 To STANFORD:
	  	Office of Technology Licensing	  	
		 		  	Stanford University	  	
		 		  	900 Welch Road, Suite 350	  	
		 		  	Palo Alto, CA 94304-1850	  	
				
		 		  	Attention: Director	  	
				
		 	To LICENSEE:	  	SunVax, Inc.	  	
		 		  	400 Hamilton Avenue,	  	
		 		  	Palo Alto, California 94305	  	
				
		 		  	Attention:	  	

  

 14 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

 Either party may change its address upon written notice to the other party. 
  

	18.	WAIVER 

 None of the terms of this Agreement
can be waived except by the written consent of the party waiving compliance. 
  

	19.	APPLICABLE LAW 

 This Agreement shall be
governed by the laws of the State of California applicable to agreements negotiated, executed and performed wholly within California. 
  

	20.	ENTIRE AGREEMENT 

 This Agreement represents
the entire agreement between STANFORD and LICENSEE relating to the subject matter of this Agreement and supersedes any previous written or oral agreements, communications, or understandings between them concerning such matters. This Agreement may be
amended only by means of a written agreement signed by authorized representatives of both parties. 
  

 15 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their
duly authorized officers or representatives. 

			
	THE BOARD OF TRUSTEES OF THE LELAND
	STANFORD JUNIOR UNIVERSITY
		
	Signature 	 	/s/ Katharine Ku

			
	Name 	 	Katharine Ku

			
	Title 	 	Director, Technology Licensing

			
	Date 	 	February 22, 2002

			
	
	LICENSEE
		
	Signature 	 	/s/ James M. Koshland

			
	Name 	 	James M. Koshland

			
	Title 	 	Secretary

			
	Date 	 	February 22, 2002

  

 16 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

 Appendix A 
 Form of Quarterly Report 
 Stanford Docket No.
S            -             
 This report is provided pursuant to the license agreement between Stanford University and                      (Licensee Name)

 License Agreement Effective Date:
                     
  

			
	 Report Covering Period
	  	
	 Fixed Fees (Annual Minimum Payment)
	  	$
	 Number of Sublicenses Executed
	  	
	 Net Sales
	  	$
	 Royalty Calculation
	  	
	 Royalty Subtotal
	  	$
	 Credit
	  	$
	 Royalty Due
	  	$

 Comments: 
  

 17 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

 Schedule B 
 Licensed Patents 
 [*] 
  

 18 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

 Schedule C 
 Proposed Inventions 
 Schedule C is attached to the Agreement recognizing that: LICENSEE has acquired
an Exclusive license to the Licensed Patents listed in Schedule B; the Parties anticipate there may be future inventions from the laboratory of Dr. Steinman in the Licensed Field of Use that Stanford intends to offer to LICENSEE for licensing
and to include in Licensed Patents as set forth in Schedule B; the Parties desire to determine the conditions under which the future inventions will be licensed by LICENSEE; since, the Parties believe that STANFORD, the LICENSEE and the public will
benefit by licensing the future inventions to LICENSEE. 
  

	1.	DEFINITIONS 

  

	 	1.1	“Proposed Invention” means a patent application or invention disclosure that STANFORD offers to LICENSEE to license as provided herein. 

  

	 	1.2	“Optioned Patent” means any patent application of any kind anywhere in the world filed on a Proposed Invention, and includes any corresponding foreign applications,
divisions, continuations, continuations-in-part (new inventions filed as part of a CIP will be subject to the provisions of Schedule C), patents of addition, patents, substitutions, registrations, reexaminations, extensions, or reissues. Optioned
Patents shall be identified as “Optioned Patents” and included in Schedule B. 

  

	 	1.3	“New Exclusive Patent” means an Optioned Patent for which LICENSEE chooses to take an Exclusive license. 

  

	 	1.4	“New Non-Exclusive Patent” means an Optioned Patent for which LICENSEE chooses to take a non-exclusive license. 

  

	2.	GRANT OF OPTION FOR EXCLUSIVE OR NON-EXCLUSIVE LICENSE 

 STANFORD
hereby grants LICENSEE and LICENSEE hereby accepts an Exclusive Option to acquire an Exclusive or non-exclusive license to Optioned Patent(s) on the terms and conditions set forth herein (“Exclusive Option”). If a future patent application
or an invention disclosure: a) names Dr. Lawrence Steinman as an inventor; and b) describes technology relating to the administration of a polynucleotide encoding an autoantigen [*] and/or diagnostics for the diseases treated by such
polynucleotide administration or technology then STANFORD will determine if that patent application or invention disclosure will become a Proposed Invention. If a patent application or invention disclosure is a Proposed Invention, then STANFORD
shall provide notice thereof to LICENSEE that LICENSEE has an Exclusive Option to license the Proposed Invention. The Proposed Invention shall be subject to this Schedule C, as well as the entirety of the Agreement. 
  

 19 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	3.	OPTION TERM 

 The Option Term shall begin when STANFORD provides
notice in writing to LICENSEE of the Proposed Invention and shall end the earlier of: 
  

	 	a)	[*] after the date STANFORD offers the Proposed Invention to LICENSEE in writing; or 

  

	 	b)	[*] after STANFORD notifies LICENSEE in writing that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for an Optioned Patent.

  

	4.	EXERCISE OF OPTION 

 LICENSEE may exercise its option at any time
during the Option Term by providing STANFORD written notice of its decision to acquire an Exclusive or non-exclusive license to the Optioned Patent set forth In such notice. Upon such notification, the Optioned Patent will become either a New
Exclusive Patent or a New Non-Exclusive Patent. A New Exclusive Patent will be subject to the terms and conditions of this Schedule C and those of any Licensed Patent under this entire Agreement. A New Non-Exclusive Patent will be subject to the
terms and conditions of this Schedule C and those of any Licensed Patent under this entire Agreement except the grant is not Exclusive. New Non-Exclusive Patent(s) may only be sublicensed as part of an alliance with a sublicensee that includes
Invention(s) that have been licensed Exclusively by LICENSEE. 
  

	5.	PAYMENTS 

  

	 	5.1	Option Fee. 

 To include Proposed Inventions in
Schedule B, LICENSEE shall pay to STANFORD [*] Dollars ($[*]) as the option fee for each Proposed Invention. If a patent application is filed on a Proposed Invention the option fee shall be paid by the later of: (i) [*] from STANFORD’s
notifying LICENSEE of a Proposed Invention; or (ii) [*] from the date a patent application is filed on a Proposed Invention. If no patent application is filed on a Proposed Invention, the option fee shall be paid by [*] from STANFORD’s
notification to LICENSEE of a Proposed Invention. After the option fee is received, a Proposed Invention will become an Optioned Patent. If LICENSEE does not pay the option fee, it relinquishes all rights to such Proposed Invention under the
Agreement. Only one such option fee is due for each Proposed Invention. 
  

	 	5.2	Non-Exclusive License Fee. 

 If LICENSEE exercises
its Exclusive Option by acquiring a non-exclusive license to an Optioned Patent, then LICENSEE shall pay to STANFORD a non-exclusive 

  

 20 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

 
license fee of [*] Dollars ($[*]) within [*] of exercising such Exclusive Option. The non-exclusive license fee is due only one time for each New
Non-Exclusive Patent. 
  

	 	5.3	Exclusive License Fee. 

 If LICENSEE decides to
exercise its Exclusive Option to acquire an exclusive license to an Optioned Patent, then LICENSEE shall pay STANFORD an exclusive license fee of [*] Dollars ($[*]) within [*] of exercising such Exclusive Option (“Exclusive License Fee”).
The amount of the Exclusive License Fee shall be agreed to by STANFORD and LICENSEE taking into account the Fee Criteria, as set forth below. If STANFORD and LICENSEE do not agree on the amount, a mutually agreeable third party will determine the
amount based on the Fee Criteria and industry standards. In any case, the amount may not be less than [*] Dollars ($[*]) and not more than [*] Dollars ($[*]). STANFORD agrees that the amount of the Exclusive License Fee will be determined taking
into account such factors as whether: (i) third party technology licensed to LICENSEE is used in conjunction with the invention claimed in the patent; (ii) the claims of the patent are method claims or are composition of matter claims that
do not encompass the product to be sold or its method of manufacture; and, (iii) LICENSEE’S financial position is that of an early stage biotechnology company (meaning that the company has not commercialized a therapeutic or diagnostic
product and has less than [*] dollars in liquid assets) (“Fee Criteria”). The Exclusive License Fee is due only once for each New Exclusive Patent. LICENSEE may convert a New Exclusive Patent to a New Non-Exclusive Patent upon written
notice to STANFORD at any time. 
  

	 	5.4	Annual Fee for New Exclusive Patents. 

 For each New
Exclusive Patent, LICENSEE shall pay to STANFORD an annual fee of [*] Dollars ($[*]). The annual fee is due beginning on the first anniversary of the date LICENSEE exercised its Exclusive Option to the Proposed Invention and each anniversary
thereafter. The amount of the annual fee shall be agreed to by STANFORD and LICENSEE taking into account the Fee Criteria. If STANFORD and LICENSEE do not agree on the amount, a mutually agreeable third party will determine the annual fee amount
based on the Fee Criteria and industry standards. In any case, the amount may not be less than [*] Dollars ($[*]) and not more than [*] Dollars ($[*]). In no event shall the cumulative amount of annual fees due under this Schedule C and the annual
fees due under Paragraph 6.3 of the Agreement exceed: i) $[*] for any one year in years [*]; ii) $[*] for any one year in years [*]; and iii) $[*] for any one year after [*]. 
  

 21 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [*] 
  

	 	5.5	Royalties. 

 For all Optioned Patents, New
Non-Exclusive Patents, and New Exclusive Patents, royalties shall be due and payable as provided in Section 6 of the Agreement. 
  

	 	5.6	Patent Expenses. 

 LICENSEE shall pay [*] patent
costs for Optioned Patents, New Exclusive Patents and New Non-Exclusive Patents. Patent costs paid by LICENSEE for New Non-Exclusive Patents shall be reimbursable as follows: 
  

	 	i)	If STANFORD licenses the patent to a third party then STANFORD shall reimburse LICENSEE for [*]% of the past patent costs paid by LICENSEE. 

  

	 	ii)	If LICENSEE chooses to convert a New Exclusive Patent to a New Non-Exclusive Patent and STANFORD licenses the New Non-Exclusive Patent to a third party then STANFORD shall reimburse
LICENSEE for [*]% of the past patent costs paid by LICENSEE. 

  

	 	iii)	Patent expenses that are not reimbursed are creditable against royalties due under paragraph 6.4 of the Agreement. 

  

	6.	DILIGENCE 

 LICENSEE shall submit to STANFORD a plan
(the “Diligence Plan”), reasonably acceptable to STANFORD, for developing a product covered by a New Exclusive Patent. The Diligence Plan will be submitted within [*] of the date LICENSEE exercises its Exclusive Option to Exclusively
license a Proposed Invention. If LICENSEE does not submit a Diligence Plan or notifies STANFORD in writing that it will no longer adhere to a Diligence Plan agreed to by STANFORD and LICENSEE, then the New Exclusive Patent will be converted to a New
Non-Exclusive Patent. 
  

	7.	SURRENDER OF OPTION OR LICENSE 

 LICENSEE may
surrender its option or license rights to a Proposed Invention, Optioned Patent, New Exclusive Patent or New Non-Exclusive Patent at any time by giving STANFORD [*] written notice of the surrender. Upon such surrender, LICENSEE shall not have any
further payment obligations pursuant to such license, other than those previously incurred, and shall not retain any rights in such Proposed Invention, Optioned Patent, New Exclusive Patent or New Non-Exclusive Patent. 
  

 22 
  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.Amendment Agreement dated November 8, 2002 to the License Agreement

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 EXHIBIT 10.5.2 
 Amendment Agreement 
 This Agreement (“Amendment Agreement”) is made and effective this 8th
day of November 2002, by and between THE BOARD OF TRUSTEES OF THE LELEAND STANFORD JUNIOR UNIVERSITY, a body having corporate powers under the laws of the State of California (“STANFORD”), and BAYHILL THERAPEUTICS, INC., (formerly named
Tolerion, Inc.) having a principal place of business at 3400 West Bayshore Road, Palo Alto, CA 94303-4227 (“BAYHILL”). 
 Recitals 
 WHEREAS, STANFORD and BAYHILL entered into an Agreement dated February 1, 2002 (“Existing
Agreement”) relating to BAYHILL’S licensing, development and commercialization of certain Inventions and Technology owned by STANFORD; 
 WHEREAS, STANFORD and BAYHILL are desirous of amending the Existing Agreement to provide for BAYHILL’S responsibility and control of the patent prosecution of the Licensed Patents and to conform the definition of the Licensed Field of
Use to the breadth of the Technology and Inventions described by the Licensed Patents; 
 NOW, THEREFORE, the parties agree as follows:

 1. Pursuant to paragraph 20 of the Existing Agreement, the parties agree to modify paragraphs 2.2 and 5.3. Paragraph 5.3 is modified to provide for
BAYHILL’S taking responsibility for and controlling the prosecution of the Licensed Patents with STANFORD having the right to review and comment. Paragraph 5.3 is amended as follows: 
 LICENSEE’S Diligent Efforts. LICENSEE shall be responsible for and shall control, at its sole cost, the preparation, filing, prosecution and
maintenance of the Licensed Patent(s). LICENSEE shall diligently and promptly apply for, seek prompt issuance of, and maintain (including payment of annuities to keep foreign applications in force) during the term of this Agreement, the Licensed
Patents. LICENSEE desires that foreign filings be made on the Inventions and STANFORD shall work closely with LICENSEE to ensure that such filings are made timely and in the order of priority reasonably requested by LICENSEE. LICENSEE shall or shall
cause the patent counsel to give STANFORD an opportunity to review and comment on the text of each patent application within the Licensed Patents before filing, and shall or shall cause the patent counsel to provide STANFORD with a copy of such
patent application as filed, together with notice of its filing date and serial number. STANFORD shall cooperate with LICENSEE, and shall make reasonable efforts to execute all lawful papers and instruments and make all rightful oaths and
declarations as may be necessary in the preparation, prosecution and maintenance of the Licensed Patents. In the event that LICENSEE desires to abandon any patent or patent application within the Licensed Patents, or take any action that would
substantially effect the scope or validity of the 

 
rights under such patent or patent application, LICENSEE shall provide notice to STANFORD a reasonable time before such abandonment or other action and
review it with STANFORD as reasonably requested, and incorporate reasonable comments by STANFORD thereon. A patent or patent application within the Licensed Patents may only be abandoned upon the mutual written agreement of the parties, provided,
however, no such mutual written agreement is required when a patent application is abandoned for the purpose of filing a continuing application. LICENSEE shall instruct patent counsel that STANFORD is the assignee of all Licensed Patents and
therefore is a client on all matters relating to the prosecution of the Licensed Patents but LICENSEE is responsible for and shall control the prosecution of Licensed Patents as provided in this Section 5.3. All Original Letters Patents issuing
on Inventions shall be maintained at STANFORD. 
 2. The definition of the “Licensed Field of Use” as set forth in paragraph 2.2 of the Existing
Agreement is hereby modified to conform the definition of the Licensed Field of Use to the breadth of the Technology and Inventions described by the Licensed Patents. Paragraph 2.2 is amended as follows: 
 “Licensed Field of Use” means therapeutics for treatment, including but not limited to prophylaxis, of human or animal diseases by the
administration of an autoantigen [*] and diagnostics for the diseases treated by such administration. The autoantigen may be administered in the form of, for example, [*]. 
 3. All other terms and conditions of the Existing Agreement shall remain in full force and effect except for modification necessary to reflect the transfer of responsibility and control of the patent prosecution to
BAYHILL and the change in the definition of the Licensed Field of Use to the breadth of the Technology and Inventions described by the Licensed Patents. 
  

			
	THE BOARD OF TRUSTEES OF THE LELAND
	STANFORD JUNIOR UNIVERSITY
		
	Signature 	 	/s/ Katharine Ku

			
	Name 	 	Katharine Ku

			
	Title 	 	Director, Technology Licensing

			
	Date	 	November 13, 2002

			
	
	BAYHILL THERAPEUTICS, INC.
		
	Signature 	 	/s/ John P. Walker

			
	Name 	 	John P. Walker

			
	Title 	 	Chairman - CEO

			
	Dated 	 	11/08/02

  

 [*] = Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]